Tags

Type your tag names separated by a space and hit enter

Urinary incontinence in men: current and developing therapy options.
Expert Opin Pharmacother. 2016; 17(5):715-26.EO

Abstract

INTRODUCTION

Urinary incontinence in men is a significant and often underappreciated problem. Men can have urgency and or stress incontinence. Urgency incontinence as part of the overactive bladder (OAB) syndrome and can often coexist with benign prostatic obstruction (BPO) in men and the initial treatment of this is conservative lifestyle changes and then medical therapy.

AREAS COVERED

This literature review aims to cover synthetic drugs currently utilised to treat urinary incontinence in men that are phase III and onwards. Neurological incontinence and surgical treatment options for male urinary incontinence are beyond the scope of this review.

EXPERT OPINION

The most common form of urinary incontinence in men is urgency incontinence secondary to an OAB, which often co-exists in men, with bladder outflow obstruction (BOO). The pharmacotherapy options to treat OAB include antimuscarinics, β3 agonists and phosphodiesterase inhibitors. Antimuscarinics and β3 agonists are effective in treating OAB, and have been found to have no increased urinary retention risk in the group of patients with co-existing BPO. Emerging medications include the alternative β3 agonists - solabegron and ritobegron. The future may include novel combinations of these therapies.

Authors+Show Affiliations

a Urology SPR , Southmead Hospital , Bristol, UK.b Head of Teaching and Research, Bristol Urological Institute, Chair, International Consultation on Urological Diseases, Bristol Urological Institute , Southmead Hospital , Bristol, UK.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

26800277

Citation

Burden, Helena, and Paul Abrams. "Urinary Incontinence in Men: Current and Developing Therapy Options." Expert Opinion On Pharmacotherapy, vol. 17, no. 5, 2016, pp. 715-26.
Burden H, Abrams P. Urinary incontinence in men: current and developing therapy options. Expert Opin Pharmacother. 2016;17(5):715-26.
Burden, H., & Abrams, P. (2016). Urinary incontinence in men: current and developing therapy options. Expert Opinion On Pharmacotherapy, 17(5), 715-26. https://doi.org/10.1517/14656566.2016.1145662
Burden H, Abrams P. Urinary Incontinence in Men: Current and Developing Therapy Options. Expert Opin Pharmacother. 2016;17(5):715-26. PubMed PMID: 26800277.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Urinary incontinence in men: current and developing therapy options. AU - Burden,Helena, AU - Abrams,Paul, Y1 - 2016/03/03/ PY - 2016/1/23/entrez PY - 2016/1/23/pubmed PY - 2016/8/26/medline KW - Urinary incontinence KW - antimuscarinic KW - male KW - overactive bladder SP - 715 EP - 26 JF - Expert opinion on pharmacotherapy JO - Expert Opin Pharmacother VL - 17 IS - 5 N2 - INTRODUCTION: Urinary incontinence in men is a significant and often underappreciated problem. Men can have urgency and or stress incontinence. Urgency incontinence as part of the overactive bladder (OAB) syndrome and can often coexist with benign prostatic obstruction (BPO) in men and the initial treatment of this is conservative lifestyle changes and then medical therapy. AREAS COVERED: This literature review aims to cover synthetic drugs currently utilised to treat urinary incontinence in men that are phase III and onwards. Neurological incontinence and surgical treatment options for male urinary incontinence are beyond the scope of this review. EXPERT OPINION: The most common form of urinary incontinence in men is urgency incontinence secondary to an OAB, which often co-exists in men, with bladder outflow obstruction (BOO). The pharmacotherapy options to treat OAB include antimuscarinics, β3 agonists and phosphodiesterase inhibitors. Antimuscarinics and β3 agonists are effective in treating OAB, and have been found to have no increased urinary retention risk in the group of patients with co-existing BPO. Emerging medications include the alternative β3 agonists - solabegron and ritobegron. The future may include novel combinations of these therapies. SN - 1744-7666 UR - https://www.unboundmedicine.com/medline/citation/26800277/Urinary_incontinence_in_men:_current_and_developing_therapy_options_ L2 - https://www.tandfonline.com/doi/full/10.1517/14656566.2016.1145662 DB - PRIME DP - Unbound Medicine ER -